Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin + albumin-bound paclitaxel + serplulimab as neoadjuvant therapy for resectable cervical esophageal squamous cell carcinoma
ChiCTR2500114965Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Zhejiang Cancer Hospital. Primary endpoints: Objective response rate and Complete response rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500114965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114965.